







Adult Community IV Antibiotic Treatment: Authorisation to Administer and Administration Record MEROPENEM 1g TDS

Patient details					Allergies & Intolerances:					Indication for treatment:														
Name																								
Address																								
											Date antibiotic to start in community:													
NHS number																								
DOB						No known allergies					Planned treatment length in community or end date:													
						Document nature, details and date of																		
						each reaction																		
eGFR: Creatinine:				Date:					Weight (kg): Date:															
Medication				Dose		Freque	requency Route			Instructions for preparation and use											narmacy check			
Meropenem				1g		TDS		IV	is o	constitute a 1g vial with 20mL of water for injections. Shake well until the sol clear (this may take some time). Reconstituted solutions should be														
Water for injections				20mL		TDS		IV		ourless to yellow and particulate free. ninistration: Give 1g by slow IV injection over 5 minutes.														
Sodium Chloride 0.9% Flush the via IV rou					cannula with 5ml of sodium chloride 0.9% or the PICC line with-10mL sodium chloride 0.9% before and after each administration e.											on								
	SPC. Meropenem 1g powder for solution for injection or infusion. Last updated: May 23. Available from Meropenem 1g powder for solution for injection or infusion - Summary of Product Characteristics (SmPC) - (emc) (medicines.org.uk)-2. edusa. Meropenem. Intravenous injection. Injectable Medicines Guide. Last updated: August 2018. Available from - https://injmed.wales.nhs.uk/IVGuideDisplay.asp																							
Date & time:																								
Given by:																								
Prescriber	must be f	2 or abo	ve, or a	suitable no	n-medic	al presc	riber.																	
Signed:	ned:				Name: (Print Name)					r	Professional registration number:				Bleep/ Telephone: Date:									

Author: Carys Jones (OPAT Pharmacist) Check by Nathalie Roberts (OPAT Pharmacist) Authorised by Medicine Governance Group

Review date: June 2025

Version 03

Approval date: June 2023